Skip to main
VIGL
VIGL logo

Vigil Neuroscience (VIGL) Stock Forecast & Price Target

Vigil Neuroscience (VIGL) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Vigil Neuroscience Inc is a clinical-stage biotechnology company focused on developing therapeutics for neurodegenerative diseases, particularly through its small molecule TREM2 agonist program, VG-3927, which has exhibited a significant dose-dependent reduction in sTREM2 and shows promise for once-daily dosing. The company's strategic partnership with Sanofi underscores its credibility and potential for commercialization, as Sanofi has secured exclusive negotiation rights for the TREM2 agonist program. With a currently negative enterprise value of $25 million and the robust Phase I data supporting its therapeutic programs, there is a perceived significant upside potential for Vigil's stock, especially with any evidence of slowing disease progression in patients.

Bears say

Vigil Neuroscience has faced a notable decline in its stock price, evidenced by a 26% decrease since the ALEC TREM2 data readout, compounded by a reported net loss of $23.8 million, translating to a GAAP EPS of $(0.57). Additionally, the company has increased its valuation discount rate to 35%, resulting in a reduced target price of $13, significantly lower than the previous target of $24, further highlighting investor concerns. Coupled with the potential risks related to failure in commercial execution and exceeding market expectations, the financial outlook for Vigil Neuroscience appears increasingly negative.

Vigil Neuroscience (VIGL) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vigil Neuroscience (VIGL) Forecast

Analysts have given Vigil Neuroscience (VIGL) a Buy based on their latest research and market trends.

According to 8 analysts, Vigil Neuroscience (VIGL) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vigil Neuroscience (VIGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.